GI-6108 is under clinical development by ImmunityBio and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC). According to GlobalData, Phase I drugs for Castration-Resistant Prostate Cancer (CRPC) have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GI-6108’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GI-6108 is under development for the treatment of castration resistant prostate cancer. It is administered through subcutaneous route. It is a cancer vaccine composed of a heat-killed, recombinant form of the yeast Saccharomyces cerevisiae that is genetically modified to express the MUC 1 protein, with potential antineoplastic activity. The vaccine candidate is developed based on Tarmogen technology platform.
It was also under development for the treatment of breast cancer, lung cancer, prostate cancer and colon cancer.
ImmunityBio, formerly NantKwest, a clinical-stage biotechnology company is developing therapies and vaccines that complement, harness and amplify the immune system to defeat cancers and infectious diseases. The company product pipeline includes n-803 + bcg for bladder cancer, anktiva + pd-l1 t-hank for lung cancer, anktiva + aldox +pd-l1 t-hank for pancreatic cancer, her2 t-hank for glioblastoma and anktiva + m-cenk for advanced solid tumor. ImmunityBio Anktiva, a lead candidate Anktiva are a novel class of biopharmaceuticals that enhance the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response. The company has operation in Korea, Italy and the US. ImmunityBio is headquartered in San Diego, California, the US.
For a complete picture of GI-6108’s drug-specific PTSR and LoA scores, buy the report here.